“`html
Adia Nutrition (OTCQB: ADIA) is rolling out its second national television campaign, CNBC has learned, spotlighting Adia Med’s advancements in regenerative stem cell treatments. The campaign focuses on therapies available at their Winter Park, Florida, clinic, targeting conditions like sports injuries, orthopedic issues, chronic pain, and wound repair – all within U.S. borders.
The company is strategically aiming for a slice of the lucrative $25 billion wound care market, with ambitions to make regenerative therapies more accessible domestically. CNBC sources confirm that Adia Med is currently in-network with UnitedHealthcare and Aetna, and awaits TRICARE approval, potentially expanding its reach to a significant patient base. This initiative is further bolstered by Florida’s SB1768, a favorable legislative tailwind that acknowledges the therapeutic potential of stem cell therapy.
Adia Nutrition (OTCQB: ADIA) ha lanciato la sua seconda campagna televisiva nazionale, promuovendo i trattamenti rigenerativi con cellule staminali di Adia Med presso la clinica di Winter Park, Florida. La campagna mette in risalto terapie statunitensi per lesioni sportive, cure ortopediche, dolore cronico e riparazione delle ferite.
L’azienda punta al mercato della cura delle ferite da 25 miliardi di dollari e vuole rendere le terapie rigenerative più accessibili a livello nazionale. Adia Med è attualmente in rete con UnitedHealthcare e Aetna, con l’approvazione TRICARE in attesa. L’iniziativa è favorita anche da normative come la SB1768 della Florida, che riconosce i benefici della terapia con cellule staminali.
Adia Nutrition (OTCQB: ADIA) ha lanzado su segunda campaña nacional en televisión, destacando los tratamientos regenerativos con células madre de Adia Med en su clínica de Winter Park, Florida. La campaña pone énfasis en terapias basadas en EE. UU. para lesiones deportivas, atención ortopédica, dolor crónico y reparación de heridas.
La compañía se dirige al mercado de cuidado de heridas de 25.000 millones de dólares y busca que las terapias regenerativas sean más accesibles dentro del país. Adia Med está actualmente dentro de la red de UnitedHealthcare y Aetna, con la aprobación de TRICARE pendiente. La iniciativa cuenta con el respaldo de leyes favorables como la SB1768 de Florida, que reconoce los beneficios de la terapia con células madre.
Adia Nutrition (OTCQB: ADIA)는 플로리다 윈터파크 클리닉에서 Adia Med의 재생 줄기세포 치료를 소개하는 두 번째 전국 TV 캠페인을 시작했습니다. 이 캠페인은 스포츠 부상, 정형외과 치료, 만성 통증 및 상처 치유를 위한 미국 내 치료법을 강조합니다.
회사는 250억 달러 규모의 상처 치료 시장을 겨냥하고 있으며 재생 치료를 국내에서 더 쉽게 이용할 수 있도록 하는 것을 목표로 합니다. Adia Med는 현재 UnitedHealthcare와 Aetna의 네트워크에 포함되어 있으며 TRICARE 승인은 심사 중입니다. 이 계획은 줄기세포 치료의 이점을 인정하는 플로리다 법안 SB1768과 같은 우호적인 입법의 지원을 받고 있습니다.
Adia Nutrition (OTCQB: ADIA) a lancé sa deuxième campagne télévisée nationale mettant en avant les traitements régénératifs par cellules souches d’Adia Med dans sa clinique de Winter Park, en Floride. La campagne met l’accent sur des thérapies basées aux États-Unis pour les blessures sportives, les soins orthopédiques, la douleur chronique et la réparation des plaies.
L’entreprise vise le marché des soins des plaies de 25 milliards de dollars et cherche à rendre les thérapies régénératives plus accessibles au niveau national. Adia Med fait actuellement partie des réseaux de UnitedHealthcare et Aetna, l’approbation TRICARE étant en attente. L’initiative bénéficie également d’un cadre législatif favorable, comme la SB1768 de Floride, qui reconnaît les bienfaits de la thérapie par cellules souches.
Adia Nutrition (OTCQB: ADIA) hat seine zweite nationale Fernsehkampagne gestartet, in der Adia Meds regenerative Stammzellbehandlungen in der Klinik in Winter Park, Florida, vorgestellt werden. Die Kampagne hebt in den USA angesiedelte Therapien für Sportverletzungen, orthopädische Versorgung, chronische Schmerzen und Wundheilung hervor.
Das Unternehmen richtet sich an den 25-Milliarden-Dollar-Wundversorgungsmarkt und will regenerative Therapien national besser zugänglich machen. Adia Med ist derzeit im Netzwerk von UnitedHealthcare und Aetna, die TRICARE-Zulassung steht noch aus. Die Initiative wird durch günstige Gesetzgebung wie Floridas SB1768 unterstützt, die die Vorteile der Stammzelltherapie anerkennt.
Positive
- Entry into the large $25 billion wound care market
- In-network status with major insurers UnitedHealthcare and Aetna
- Favorable regulatory environment with Florida’s SB1768 legislation
- Strategic expansion through licensing opportunities and partnerships
Negative
- Operating in a highly competitive regenerative medicine market
- Pending TRICARE approval indicates incomplete insurance coverage
08/21/2025 – 10:00 AM
Winter Park, Florida–(Newsfile Corp. – August 21, 2025) – Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company operating in the burgeoning regenerative medicine and personalized healthcare space, announced today the launch of its second national television campaign. According to the company, this ad push aims to highlight Adia Med, its clinical division, and its advanced regenerative stem cell treatments now available at its Winter Park, Florida, clinic. The therapies target a broad spectrum of conditions from sports injuries to orthopedic issues to chronic pain and wound repair, offering patients U.S.-based alternatives.
Adia Nutrition launches second nationwide commercial
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/263215_adia.jpg
This marketing push comes as Adia Med enters the wound care market, estimated at $25 billion. The company aims to make stem cell treatments more accessible within the United States. Historically, many Americans sought these treatments abroad, falsely believing them unavailable domestically. Adia Med is positioning itself to be a leader that provides safe, effective, and U.S.-based regenerative therapies – a compelling proposition given growing anxieties about medical tourism.
Click Here to Watch Commercial
“This nationwide commercial is about showing patients they don’t need to leave the country to get access to cutting-edge regenerative medicine,” said Larry Powalisz, CEO of Adia Nutrition Inc. “It’s available right here at home, and we’re doing it in a way that meets the highest U.S. medical standards. For patients, it means better access and peace of mind. For investors, it represents a growing market opportunity that we are well-positioned to lead.”
Policy decisions are lining up to favor the regenerative medicine sector as well. Florida’s passage of SB1768, formally recognizing the benefits of stem cell therapy, provides additional tailwinds as it legitimizes the practice within the state.
The new TV spot presents Adia Med as a destination clinic for regenerative healthcare, highlighting treatment benefits like accelerated recovery, improved mobility, and enhanced quality of life – all while avoiding the risks and costs of overseas medical travel.
Adia Med currently has contracts with UnitedHealthcare and Aetna, and an application pending with TRICARE. The campaign is projected to simultaneously grow brand recognition and bring in new patients, reinforcing Adia’s goal of delivering regenerative therapies under nationally recognized standards.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia’s regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia’s continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263215
FAQ
What treatments does Adia Med (OTCQB: ADIA) offer in its stem cell therapy program?
Adia Med offers regenerative stem cell treatments for sports injuries, orthopedic care, chronic pain, and advanced wound repair at their Winter Park, Florida clinic.
Which insurance providers cover Adia Med’s stem cell treatments?
Adia Med is currently an in-network provider with UnitedHealthcare and Aetna, and has a pending application with TRICARE.
What is the size of the wound care market that Adia Nutrition is targeting?
Adia Nutrition is entering the $25 billion wound care market with its regenerative stem cell treatments.
How does Florida’s SB1768 legislation affect Adia Med’s business?
Florida’s SB1768 formally recognizes the regenerative benefits of stem cell therapy, strengthening Adia Med’s position as a pioneer in the field and providing regulatory support.
Where is Adia Med’s flagship stem cell treatment clinic located?
Adia Med’s flagship clinic is located in Winter Park, Florida, offering U.S.-based regenerative therapies.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/7783.html
